The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

In 2025, we will also target diabetic retinopathy. Our HELIOS study has demonstrated that a single injection of AXPAXLI has the potential to reduce the risk of vision loss in NPDR to literally zero at ...

The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal Axitinib implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy ...

Adults with type 2 diabetes who initiated empagliflozin or DPP4i therapy were divided into two groups: 34,239 matched pairs for evaluating the risk of developing new NPDR and 7,831 matched pairs ...

DR was found in 140 patients (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate NPDR, 22 patients (11.1%) with severe NPDR and 25 ...

Aims To determine the effect of diabetes on inner and outer retinal function in persons with diabetes and no clinically detectable retinopathy or with non-proliferative diabetic retinopathy (NPDR).

Our HELIOS study has demonstrated that a single injection of AXPAXLI has the potential to reduce the risk of vision loss in NPDR to literally zero at 48 weeks. In HELIOS, every single patient with ...

Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P ...

In 2025, we will also target diabetic retinopathy. Our HELIOS study has demonstrated that a single injection of AXPAXLI has the potential to reduce the risk of vision loss in NPDR to literally zero at ...